Utility of the Superior Vena Cava Collapsibility Index (SVC-CI) to Predict Fluid Responsiveness in Patients With Coronary Artery Disease Undergoing Surgical Revascularization

Last updated: April 18, 2025
Sponsor: Milton S. Hershey Medical Center
Overall Status: Active - Recruiting

Phase

N/A

Condition

Myocardial Ischemia

Atherosclerosis

Thrombosis

Treatment

a change in operating room table position, which will mimic an IV fluid bolus

Clinical Study ID

NCT06645327
STUDY 24328
Study 24328
  • Ages > 18
  • All Genders

Study Summary

To investigate the superior vena cava collapsibility index (SVC-CI), measured via transesophageal echocardiography (TEE), as a marker of fluid responsiveness. Two groups will be compared in this study. Groups will be identified by obtaining cardiac output (CO) by standard means using the TEE or pulmonary arterial catheter (PAC). Both of these monitors are considered standard for patient's undergoing coronary artery bypass grafting surgery (CABG) and recording initial CO readings. Based on CO, the patient's will be placed in study groups one or two. Participants with normal and mildly reduced left ventricular ejection fraction (LVEF >40%) for group one and those with moderately to severely reduced LVEF (<40%) in the second group.

Following group separation, we will measure the SVC-CI and CO metric in both groups. The intervention will be an operating room table tilt test (head up and then head down) to artificially simulate giving the patient additional fluid. Before and after table tilt, the SVC-CI and CO will be obtained and measured. The SVC-CI is a mathematical equation determined by distance measurements taken via TEE to identify how much the superior vena cava has collapsed following table tilt. Participants will be considered responders if the CO increases by 12% following intervention. Non responders less than 12% change in CO following intervention. Our hypothesis is that the SVC-CI can differentiate responders vs non-responders with regards to fluid responsiveness with adequate sensitivity and specificity in participants with CAD undergoing isolated CABG. The SVC-CI numerical values for the two groups, responders and non-responders, will calculate a threshold of sensitivity and specificity percentages for future patients undergoing CABG.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Age ≥ 18

  2. Participants with CAD undergoing CABG utilizing cardiopulmonary bypass

  3. Participants who are able to consent for themselves

  4. Primary language is English

Exclusion

Exclusion Criteria:

  1. Age less than 18 years of age

  2. Participants with CAD undergoing off-pump coronary artery bypass (OP-CAB)

  3. Severe cardiac valvular pathologies or active congestive heart failure

  4. Participants in active arrhythmia such as atrial fibrillation and atrial flutter atthe time of data collection.

  5. Participants who are unable to consent for themselves

  6. Primary language is something other than English

Study Design

Total Participants: 120
Treatment Group(s): 1
Primary Treatment: a change in operating room table position, which will mimic an IV fluid bolus
Phase:
Study Start date:
February 24, 2025
Estimated Completion Date:
January 31, 2029

Connect with a study center

  • Penn State Hershey Medical Center

    Hershey, Pennsylvania 17033
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.